Mineralocorticoid receptor antagonism may provide a novel treatment option for complex dry eye patients with not only aqueous deficiency but also inflammatory and evaporative etiologies of dry eye. The gene discussed is NR3C2; the disease is Keratoconjunctivitis sicca.